Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (850) 850
science & technology (599) 599
hiv infections - drug therapy (595) 595
dideoxynucleosides - adverse effects (582) 582
life sciences & biomedicine (576) 576
male (442) 442
anti-hiv agents - adverse effects (418) 418
female (405) 405
dideoxynucleosides - therapeutic use (402) 402
adult (368) 368
infectious diseases (361) 361
anti-hiv agents - therapeutic use (291) 291
middle aged (290) 290
abacavir (271) 271
biological and medical sciences (239) 239
medical sciences (237) 237
antiviral agents (227) 227
hiv (222) 222
dideoxynucleosides - administration & dosage (219) 219
reverse transcriptase inhibitors - adverse effects (216) 216
pharmacology. drug treatments (183) 183
aids/hiv (179) 179
immunology (178) 178
pharmacology & pharmacy (178) 178
drug therapy, combination (176) 176
lamivudine - therapeutic use (163) 163
reverse transcriptase inhibitors - therapeutic use (160) 160
anti-hiv agents - administration & dosage (151) 151
drug combinations (140) 140
viral diseases (140) 140
antibiotics. antiinfectious agents. antiparasitic agents (139) 139
virology (132) 132
drug therapy (128) 128
human viral diseases (128) 128
hla-b antigens - genetics (127) 127
lamivudine - adverse effects (126) 126
lamivudine - administration & dosage (123) 123
treatment outcome (121) 121
human immunodeficiency virus--hiv (118) 118
viral diseases of the lymphoid tissue and the blood. aids (117) 117
cd4 lymphocyte count (116) 116
drug hypersensitivity - genetics (116) 116
antiretroviral drugs (115) 115
tenofovir (109) 109
hiv infections - virology (105) 105
microbiology (105) 105
risk factors (103) 103
adenine - analogs & derivatives (101) 101
viral load (100) 100
hiv infection (99) 99
aged (94) 94
hiv infections - complications (94) 94
hiv-1 (94) 94
antiretroviral therapy (89) 89
zidovudine - therapeutic use (83) 83
pharmacogenetics (82) 82
lamivudine (80) 80
hiv infections - immunology (79) 79
drug hypersensitivity - etiology (75) 75
antiretroviral therapy, highly active - adverse effects (73) 73
hiv-1 - drug effects (73) 73
zidovudine - adverse effects (73) 73
antiretroviral therapy, highly active (71) 71
reverse transcriptase inhibitors - administration & dosage (70) 70
abridged index medicus (67) 67
adenine - therapeutic use (67) 67
adolescent (66) 66
human immunodeficiency virus (66) 66
aids (65) 65
clinical trials (64) 64
general & internal medicine (62) 62
health aspects (62) 62
medicine, general & internal (62) 62
research (62) 62
zidovudine - administration & dosage (61) 61
dideoxynucleosides - pharmacology (58) 58
highly active antiretroviral therapy (58) 58
benzoxazines (57) 57
care and treatment (57) 57
hiv protease inhibitors - therapeutic use (55) 55
prospective studies (55) 55
retrospective studies (55) 55
rna, viral - blood (55) 55
drug hypersensitivity - immunology (54) 54
adenine - adverse effects (53) 53
emtricitabine (53) 53
drug administration schedule (52) 52
organophosphonates - therapeutic use (52) 52
drug hypersensitivity (51) 51
clinical trials as topic (50) 50
dideoxynucleosides (50) 50
immunopathology (50) 50
dideoxynucleosides - pharmacokinetics (49) 49
hypersensitivity (49) 49
young adult (49) 49
immunodeficiencies (48) 48
immunodeficiencies. immunoglobulinopathies (48) 48
dosage and administration (47) 47
hiv patients (47) 47
analysis (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (842) 842
German (18) 18
Spanish (11) 11
French (10) 10
Italian (3) 3
Russian (3) 3
Chinese (2) 2
Japanese (2) 2
Portuguese (2) 2
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
by Grace A. McComsey and Douglas Kitch and Eric S. Daar and Camlin Tierney and Nasreen C. Jahed and Pablo Tebas and Laurie Myers and Kathleen Melbourne and Belinda Ha and Paul E. Sax
The Journal of infectious diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
by Abgrall, Sophie and Antiretroviral Therapy Cohort Coll and Antiretroviral Therapy Cohort Collaboration (ART-CC)
AIDS (London), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens
by Anastos, Kathryn and Lu, Dalian and Shi, Qiuhu and Tien, Phyllis C and Kaplan, Robert C and Hessol, Nancy A and Cole, Steven and Vigen, Cheryl and Cohen, Mardge and Young, Mary and Justman, Jessica
Journal of acquired immune deficiency syndromes (1999), ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Microbiology | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Virology | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection | Antiretroviral drugs | Drug therapy | Multivariate analysis | Human immunodeficiency virus--HIV | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging
by Edwin Leeansyah and Paul U. Cameron and Ajantha Solomon and Surekha Tennakoon and Pushparaj Velayudham and Maelenn Gouillou and Tim Spelman and Anna Hearps and Christopher Fairley and Anna B. Pierce and Jude Armishaw and Suzanne M. Crowe and David A. Cooper and Kersten K. Koelsch and Jun-Ping Liu and John Chuah and Sharon R. Lewin
The Journal of infectious diseases, ISSN 0022-1899, 4/2013, Volume 207, Issue 7, pp. 1157 - 1165
T lymphocytes | HIV/AIDS | Telomeres | Antiretrovirals | HIV | Final causes | Cell lines | Nucleosides | Reverse transcriptase inhibitors | Carts | Disease risks | telomerase | aging | HIV infection | antiretroviral therapy | telomere | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Biological and medical sciences | Medical sciences | Virology | Humans | Middle Aged | Aging - drug effects | Antiretroviral Therapy, Highly Active - adverse effects | Male | Telomere - drug effects | Case-Control Studies | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Young Adult | Telomere Shortening | Adenine - adverse effects | HIV Infections - pathology | Time Factors | Polymerase Chain Reaction | Adult | Deoxycytidine - adverse effects | Female | Telomerase - metabolism | Dideoxynucleosides - adverse effects | Emtricitabine | Adenine - analogs & derivatives | Leukocytes, Mononuclear - drug effects | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Cells, Cultured | Organophosphonates - adverse effects | HIV - pathogenicity | Enzyme Activation - drug effects | Regression Analysis | Telomere - enzymology | HIV Infections - drug therapy | Leukocytes, Mononuclear - enzymology | Telomerase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Complications and side effects | Demographic aspects | Physiological aspects | Aging | Research | Telomerase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
by Smith, Kimberly Y and Patel, Parul and Fine, Derek and Bellos, Nicholaos and Sloan, Louis and Lackey, Philip and Kumar, Princy N and Sutherland-Phillips, Denise H and Vavro, Cindy and Yau, Linda and Wannamaker, Paul and Shaefer, Mark S and HEAT Study Team
AIDS (London), ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury
by Kaniwa, Nahoko and Saito, Yoshiro
Journal of human genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Flucloxacillin | Risk groups | DQA1 protein | Allopurinol | Hypersensitivity | Liver | Drug development | Carbamazepine | Genetic screening | Ticlopidine | Quality of life | Side effects | Genetic markers | Abacavir | Histocompatibility antigen HLA | Pharmacogenomics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study
by Post, Frank A and Moyle, Graeme J and Stellbrink, Hans Jürgen and Domingo, Pere and Podzamczer, Daniel and Fisher, Martin and Norden, Anthony G and Cavassini, Matthias and Rieger, Armin and Khuong-Josses, Marie-Aude and Branco, Teresa and Pearce, Helen C and Givens, Naomi and Vavro, Cindy and Lim, Michael L
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 49 - 57
HIV-1 | Efficacy | Abacavir/lamivudine | Tenofovir/emtricitabine | Cardiovascular | Renal | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Glomerular Filtration Rate - drug effects | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | beta 2-Microglobulin - urine | Benzoxazines - adverse effects | Treatment Outcome | Retinol-Binding Proteins - urine | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations | Proteins | Antiretroviral drugs | Human immunodeficiency virus--HIV | Clinical trials | Adults | Drug therapy | Binding sites | Effectiveness studies | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
by Friis-Møller, Nina and Ryom, Lene and Smith, Colette and Weber, Rainer and Reiss, Peter and Dabis, F and de Wit, Stephane and Monforte, Antonella D.'Arminio and Kirk, Ole and Fontas, Eric and Sabin, Caroline and Phillips, Anew and Lundgren, Jens and Law, Matthew and DAD Study Grp and D:A:D study group
European journal of preventive cardiology, ISSN 2047-4881, 2016, Volume 23, Issue 2, pp. 214 - 223
epidemiology | AIDS | CVD risk prediction | HIV | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Blood Pressure | Genetic Predisposition to Disease | Prospective Studies | Age Factors | Risk Assessment | Lipoproteins, HDL - blood | Cholesterol - blood | HIV Infections - epidemiology | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Models, Statistical | HIV Protease Inhibitors - therapeutic use | Smoking - epidemiology | Diabetes Mellitus - epidemiology | Sex Factors | Cardiovascular Diseases - epidemiology | Adult | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
by Molina, Jean-Michel and Ward, Douglas and Brar, Indira and Mills, Anthony and Stellbrink, Hans-Jürgen and López-Cortés, Luis and Ruane, Peter and Podzamczer, Daniel and Brinson, Cynthia and Custodio, Joseph and Liu, Hui and Andreatta, Kristen and Martin, Hal and Cheng, Andrew and Quirk, Erin
The lancet HIV, ISSN 2352-3018, 07/2018, Volume 5, Issue 7, pp. e357 - e365
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | Emtricitabine - administration & dosage | Dideoxynucleosides - administration & dosage | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | HIV Seropositivity | Tenofovir - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Heterocyclic Compounds, 4 or More Rings - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | HIV Infections - drug therapy | Aged | Sustained Virologic Response | Drug Substitution | Viral Load - drug effects | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights